{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:27:09Z","timestamp":1786602429596,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>IL-17 pathway inhibitors are established treatments for active psoriatic arthritis (PsA), but comparative evidence within this therapeutic class remains limited. We compared the efficacy, safety, treatment rankings, and certainty of evidence for established and emerging IL-17 pathway inhibitors in adults with active PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a PRISMA-compliant systematic review and network meta-analysis. MEDLINE via PubMed, Embase via Ovid, CENTRAL, ClinicalTrials.gov, and the EU Clinical Trials Register were searched from January 1, 2010, to January 18, 2026. Eligible studies were phase 2 or phase 3 randomized controlled trials in adults with PsA. The primary outcome was ACR50 at Weeks 12\u201316. Secondary outcomes included ACR20, ACR70, PASI90, minimal disease activity, HAQ-DI, safety outcomes, Week-24 outcomes, and descriptive Week-52 outcomes. Frequentist random-effects network meta-analysis was performed; certainty was assessed using CINeMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen RCTs were included. The primary ACR50 network comprised eight RCTs and ten treatment nodes. All active treatments were superior to placebo for ACR50 at Weeks 12\u201316, with negligible heterogeneity (\u03c4\u00b2 = 0; I\u00b2 = 0%) and no important incoherence. Ixekizumab Q2W had the highest ACR50 P-score, followed by bimekizumab 160 mg with loading and ixekizumab Q4W; however, active-treatment confidence intervals overlapped. Secondary outcomes showed consistent improvements in joint, skin, multidomain, and functional endpoints. Sonelokimab and izokibep showed favorable exploratory estimates but very low certainty. Serious adverse events and discontinuations were not clearly increased versus placebo. Bimekizumab showed a modest increase in infection risk and a higher Candida signal; IBD events were rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IL-17 pathway inhibitors are effective short-term treatments for active PsA. Rankings suggest potential within-class differences, but indirect comparisons and overlapping confidence intervals limit definitive superiority claims. Candida risk and patient-specific factors should inform individualized treatment selection. The protocol was registered in PROSPERO (CRD420251156756).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251156756<\/jats:ext-link>\n                      , identifier CRD420251156756.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1893092","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:32:38Z","timestamp":1786599158000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Yahya Kayed","family":"AbuJwaid","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas K.","family":"Assi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhareth M.","family":"Amro","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habeeb H.","family":"Awwad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ehmidat","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Alexandria University","place":["Alexandria, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salahaldeen","family":"Deeb","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad W.","family":"Awlad Mohammad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Dwayat","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Odeh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Albow","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Yasini","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alfrookh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith","family":"Alamlih","sequence":"additional","affiliation":[{"name":"Rheumatology department, Al-Mezan Hospital","place":["Hebron, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054901","article-title":"Psoriatic arthritis: pathogenesis and targeted therapies","volume":"24","author":"Azuaga","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae198","article-title":"The worldwide prevalence of psoriatic arthritis\u2014a systematic review and meta-analysis","volume":"63","author":"Lembke","year":"2024","journal-title":"Rheumatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3899\/jrheum.200371","article-title":"Effect of multidomain disease presentations on patients with psoriatic arthritis in the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"48","author":"Ogdie","year":"2020","journal-title":"J Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1759720X241295920","DOI":"10.1177\/1759720x241295920","article-title":"The impact of psoriatic arthritis on quality of life: a systematic review","volume":"16","author":"James","year":"2024","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheumatic Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2017.17037","article-title":"Targeting IL-17 in psoriatic arthritis","volume":"4","author":"Wang","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040052","article-title":"The role of IL-17 in protection against mucosal candida infections","volume":"3","author":"Mengesha","year":"2017","journal-title":"J Fungi"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-26","article-title":"Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis","volume":"15","author":"Cawson","year":"2014","journal-title":"BMC Musculoskeletal Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000484520","article-title":"TH17 inhibitors in active psoriatic arthritis: A systematic review and meta-analysis of randomized controlled clinical trials","volume":"233","author":"Naik","year":"2017","journal-title":"Dermatology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1654343","article-title":"Efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials","volume":"16","author":"Gao","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk\u2010of\u2010bias VISualization (robvis): An R package and Shiny web app for visualizing risk\u2010of\u2010bias assessments","volume":"12","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2022","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/art.42997","article-title":"Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: results from a randomized, Placebo\u2010Controlled Phase 3 study","volume":"77","author":"Kivitz","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheumatic Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2016","journal-title":"Ann Rheumatic Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00250-3","article-title":"Efficacy and safety of ixekizumab with or without methotrexate in biologic-na\u00efve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study","volume":"7","author":"Smolen","year":"2020","journal-title":"Rheumatol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2022","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20413","article-title":"Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate\u2010to\u2010severe plaque psoriasis: results from EXCEED, a randomized, double\u2010blind head\u2010to\u2010head monotherapy study","volume":"185","author":"Gottlieb","year":"2021","journal-title":"Br J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03971-6","article-title":"Sonelokimab, an IL-17A\/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial","volume":"31","author":"McInnes","year":"2025","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.019","article-title":"Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"84","author":"Taylor","year":"2025","journal-title":"Ann Rheumatic Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2021.1967748","article-title":"Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis","volume":"17","author":"Ali","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500909","article-title":"IL-17\u2013mediated immunity to the opportunistic fungal pathogen Candida albicans","volume":"195","author":"Conti","year":"2015","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:32:40Z","timestamp":1786599160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1893092"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1893092","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1893092"}}